Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Mesenchymal Stem Cell‐Mediated Reversal of Bronchopulmonary Dysplasia and Associated Pulmonary Hypertension

Open access
Hansmann, Georg, Fernandez‐Gonzalez, Angeles, Aslam, Muhammad, Vitali, Sally H., Martin, Thomas, Mitsialis, S. Alex, Kourembanas, Stella · 2012 · Pulmonary Circulation

Abstract

Clinical trials have failed to demonstrate an effective preventative or therapeutic strategy for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disease in preterm infants frequently complicated by pulmonary hypertension (PH). Mesenchymal stem cells (MSCs) and their secreted components have been shown to prevent BPD and pulmonary fibrosis in rodent models. We hypothesized that treatment with conditioned media (CM) from cultured mouse bone marrow‐derived MSCs could reverse hyperoxia‐induced BPD and PH. Newborn mice were exposed to hyperoxia (FiO 2=0.75) for two weeks, were then treated with one intravenous dose of CM from either MSCs or primary mouse lung fibroblasts (MLFs), and placed in room air for two to four weeks. Histological analysis of lungs harvested at four weeks of age was performed to determine the degree of alveolar injury, blood vessel number, and vascular remodeling. At age six weeks, pulmonary artery pressure (PA acceleration time) and right ventricular hypertrophy (RVH; RV wall thickness) were assessed by echocardiography, and pulmonary function tests were conducted. When compared to MLF‐CM, a single dose of MSC‐CM‐treatment (1) reversed the hyperoxia‐induced parenchymal fibrosis and peripheral PA devascularization (pruning), (2) partially reversed alveolar injury, (3) normalized lung function (airway resistance, dynamic lung compliance), (4) fully reversed the moderate PH and RVH, and (5) attenuated peripheral PA muscularization associated with hyperoxia‐induced BPD. Reversal of key features of hyperoxia‐induced BPD and its long‐term adverse effects on lung function can be achieved by a single intravenous dose of MSC‐CM, thereby pointing toward a new therapeutic intervention for chronic lung diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/2045-8932.97603

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 234

Metadata

Authors
Hansmann, G., Fernandez‐Gonzalez, A., Aslam, M., Vitali, S. H., Martin, T., Mitsialis, S. A., & Kourembanas, S.
Venue
Pulmonary Circulation
Publisher
Wiley
Published
2012-04
Volume
2
Issue
2
Pages
170-181
ISSN
  • 2045-8932 (ISSN-L)
  • 2045-8940
OpenAlex
W2157499746
Cited by
234
References
3
FWCI
13.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal Stem Cell‐Mediated Reversal of Bronchopulmonary Dysplasia and Associated Pulmonary Hypertension. https://app.cochat.ai/papers/10.4103/2045-8932.97603
The paper
Hansmann, G., Fernandez‐Gonzalez, A., Aslam, M., Vitali, S. H., Martin, T., Mitsialis, S. A., & Kourembanas, S. (2012). Mesenchymal Stem Cell‐Mediated Reversal of Bronchopulmonary Dysplasia and Associated Pulmonary Hypertension. Pulmonary Circulation. https://doi.org/10.4103/2045-8932.97603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.